


COVID-19 Vaccine Clinical Trial Support

Accelerated Enrollment Solutions (AES) is fully engaged in supporting accelerated vaccine development efforts to combat the global coronavirus (COVID-19) outbreak.

With our AES Sites & Patients solution we offer COVID-19 trial sponsors greater clinical trial speed, certainty and control through:

- Expertise from 1,000+ vaccine studies completed across the entire spectrum, including emerging diseases and pandemics such as Ebola, H7N9 and H1N1
- More than 160 owned and partnered research sites worldwide dedicated exclusively to clinical research
- Surge capacity for high-volume clinical trials (e.g., full utilization of our surge capacity can generate 5,000+ subjects in a single week)



- Flexible site enrollment strategy to take into account epidemiological trends and hotspots
- Centralized control and standardized global operating procedures for fast, synchronized site activation worldwide
- Extensive First-in-Human/Phase I-III experience
- Advanced PBMC lab capabilities
- Highly trained research staff
- All service fees (start-up, recruitment, operational management) are offered under results-based, pay-per-randomization commercial terms, demonstrating our commitment to shared-risk and value in the delivery of our services

DIVERSITY AND AES RECRUITMENT:

AES has a history of success recruiting diverse patient populations. For example, during a 1-year period ending in 2019, AES pre-screened 417,000 African American respondents out of a total of over 3,000,000 respondents, approximately the same percentage of the African-American population in the US.

In recent COVID-19 vaccine trials, which is disproportionately affecting persons of color, AES has helped several sponsors achieve their recruitment targets. In one example, targeted recruitment resulted in 46% of AES subjects from diverse backgrounds. We have been acknowledged by Operation Warp Speed and the FDA for this work.




AES Sites & Patients was named Best Clinical Site Network at the 2019 Vaccine Industry Excellence (ViE) Awards.



10,000

candidates screened daily



160+

locations

Access to **100 million** households

Sponsors that engage our AES Sites & Patients solution leverage the **10,000 candidates** that AES screens daily to pre-pool candidates at our high-capacity sites.

The AES database of over **100 million households** coupled with of more than **160 research sites** worldwide give us an unequalled ability to find, engage and retain massive numbers of subjects at scale.

REACHING DIVERSE POPULATIONS:

Recognizing the importance of diversity in clinical trials, AES offers a wide variety of solutions for the issues faced by many in the African American and other communities of color, including **transportation and expense reimbursement**. In addition, we have **flexible, online patient-directed scheduling, virtual first office visits, and home healthcare visits** where available.

The AES **patient database** includes 11 million individuals self-identified as belonging to a community of color across multiple therapeutic areas.

AES utilizes its wide range of **marketing channels** to achieve the broadest reach, and focuses on diversity specific media outlets:

- Direct-to-Subject Communications (Direct Mail, Email, Phone, Text)
- Traditional Media (TV, Print, Radio, Billboards, Transit, etc.)
- Online Marketing (Search, Display, Content Marketing, Retargeting, etc.)
- Social Media (Facebook, Twitter, Pinterest, Reddit, Instagram, Bloggers/Influencers, etc.)
- Target Cohort Focused Media Outlets (BET, Telemundo)
- AES Proprietary Partnership Network (Online Health and Survey Networks/Communities, Advocates, etc.)

When racial/ethnic information is not available, AES utilizes various database methodologies (including publicly available ZIP code overlays and **proprietary data modeling algorithms**) to approximate race/ethnic population concentrations and expand our reach to targeted diverse populations with a high level of confidence.

BEST PRACTICES FOR DIVERSITY RECRUITMENT DURING COVID:

AES regularly incorporates diversity considerations when planning sites and study design:

- In site selection, including geographies with diverse populations and access to public transportation
- Including multicultural physicians in the site network
- Culturally educating all staff
- Offering weekend or after work hours and telehealth options
- Evaluating and flagging I/E criteria in protocols that may impact target cohort participation

We are committed to creating consistent, bi-directional community partnerships and engagement:

- Engaging with diverse subjects and their community groups to eliminate barriers to trial participation
- Building trust; “meeting people where they live” (e.g., outreach at community events, churches and barbershops)
- Partnering with local hospital systems offering services to populations in need

And we take diverse populations into consideration when planning trial communications:

- Translating subject materials into multiple languages
- Incorporating culturally appropriate images and messaging
- Partnering with local advocacy groups to disseminate clinical trial information to potential subjects